Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 4/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15096664 | 0.74 | LIPG (0.42) | LPLLIPGROCK1BACE1IRAK4 | |
| SCHEMBL21674425 | 0.74 | LPL (0.35) | LPLLIPGROCK1BACE1IRAK4 | |
| SCHEMBL13731679 | 0.74 | NOTUM (0.39) | LPLLIPGROCK1BACE1IRAK4 | |
| SCHEMBL23564363 | 0.73 | ROCK1 (0.37) | LPLLIPGROCK1BACE1IRAK4 | |
| SCHEMBL21024161 | 0.72 | LPL (0.40) | LPLLIPGROCK1IRAK4CA1 | |
| SCHEMBL17948555 | 0.71 | MEN1 (0.38) | LPLLIPGROCK1BACE1IRAK4 | |
| SCHEMBL14822226 | 0.71 | BACE1 (0.39) | LPLLIPGROCK1BACE1CA1 | |
| SCHEMBL24347623 | 0.71 | LPL (0.33) | LPLLIPGROCK1BACE1 | |
| SCHEMBL31394828 | 0.71 | ROCK1 (0.44) | LPLLIPGROCK1BACE1IRAK4 | |
| SCHEMBL20206428 | 0.71 | LPL (0.42) | LPLLIPGROCK1IRAK4CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| EP-2717694-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Limited (GB) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012170752-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155375-A1 | NOVEL COMPOUNDS | CYBB, NOX1, NOX4 | LPL 1212/4885LIPG 350/4885ROCK1 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.